rs397514648
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 11P and 1B. PM2PP3PP5_Very_StrongBS1_Supporting
The NM_014239.4(EIF2B2):c.254T>A(p.Val85Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000385 in 1,611,862 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000039 ( 0 hom. )
Consequence
EIF2B2
NM_014239.4 missense
NM_014239.4 missense
Scores
13
5
1
Clinical Significance
Conservation
PhyloP100: 7.95
Genes affected
EIF2B2 (HGNC:3258): (eukaryotic translation initiation factor 2B subunit beta) This gene encodes the beta subunit of eukaryotic initiation factor-2B (EIF2B). EIF2B is involved in protein synthesis and exchanges GDP and GTP for its activation and deactivation. [provided by RefSeq, Aug 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.825
PP5
Variant 14-75003365-T-A is Pathogenic according to our data. Variant chr14-75003365-T-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 40180.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr14-75003365-T-A is described in Lovd as [Pathogenic].
BS1
Variant frequency is greater than expected in population eas. gnomad4_exome allele frequency = 0.000039 (57/1461828) while in subpopulation EAS AF= 0.00136 (54/39700). AF 95% confidence interval is 0.00107. There are 0 homozygotes in gnomad4_exome. There are 27 alleles in male gnomad4_exome subpopulation. Median coverage is 33. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
EIF2B2 | NM_014239.4 | c.254T>A | p.Val85Glu | missense_variant | 2/8 | ENST00000266126.10 | NP_055054.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EIF2B2 | ENST00000266126.10 | c.254T>A | p.Val85Glu | missense_variant | 2/8 | 1 | NM_014239.4 | ENSP00000266126.5 |
Frequencies
GnomAD3 genomes AF: 0.0000333 AC: 5AN: 150034Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
5
AN:
150034
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000717 AC: 18AN: 251012Hom.: 0 AF XY: 0.0000590 AC XY: 8AN XY: 135670
GnomAD3 exomes
AF:
AC:
18
AN:
251012
Hom.:
AF XY:
AC XY:
8
AN XY:
135670
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000390 AC: 57AN: 1461828Hom.: 0 Cov.: 33 AF XY: 0.0000371 AC XY: 27AN XY: 727194
GnomAD4 exome
AF:
AC:
57
AN:
1461828
Hom.:
Cov.:
33
AF XY:
AC XY:
27
AN XY:
727194
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000333 AC: 5AN: 150034Hom.: 0 Cov.: 31 AF XY: 0.0000274 AC XY: 2AN XY: 73110
GnomAD4 genome
AF:
AC:
5
AN:
150034
Hom.:
Cov.:
31
AF XY:
AC XY:
2
AN XY:
73110
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
10
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Leukoencephalopathy with vanishing white matter 2 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PM3_VeryStrong+PS3_Supporting+PP1 - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 2011 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change replaces valine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 85 of the EIF2B2 protein (p.Val85Glu). This variant is present in population databases (rs397514648, gnomAD 0.1%). This missense change has been observed in individuals with leukoencephalopathy with vanishing white matter (PMID: 21484434, 25031760, 25843247, 28041799, 29700822). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 40180). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt EIF2B2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects EIF2B2 function (PMID: 21484434). For these reasons, this variant has been classified as Pathogenic. - |
Abnormality of the nervous system Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Kariminejad - Najmabadi Pathology & Genetics Center | Jul 10, 2021 | - - |
Vanishing white matter disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 17, 2023 | Variant summary: EIF2B2 c.254T>A (p.Val85Glu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 7.2e-05 in 251012 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in EIF2B2 causing Leukoencephalopathy With Vanishing White Matter (7.2e-05 vs 0.00046), allowing no conclusion about variant significance. c.254T>A has been reported in the literature in multiple homozygous and compound heterozygous individuals affected with Leukoencephalopathy With Vanishing White Matter (Matsukawa_2011, Shimada_2015, Lee_2017, Wei_2019). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, showing the variant results in ~80% of normal GDP/GTP exchange activity (Matsukawa_2011). Two submitters have provided clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Pathogenic
D
Sift4G
Pathogenic
D
Polyphen
D
Vest4
MutPred
Gain of disorder (P = 0.0084);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at